The 15th biannual International Congress of the International Society of Cardiovascular Pharmacotherapy (ISCP) will be held on October 11–12, 2009 in Beijing in collaboration with the annual Great Wall International Congress of Cardiology.

An exciting structured program has been finalized covering a wide range of contemporary issues in drug therapy for cardiovascular diseases. A feature of the program will be the Henry Neufeld Memorial Lecture given this year by Juan Carlos Kaski, Vice-President of ISCP. Poster sessions of selected submitted abstracts will provide an opportunity for wider participation. Young Investigator Awards will be bestowed on those abstracts from young researchers selected for excellence by a review committee.

The program for the meeting is shown below.

Jay N. Cohn, M.D, President

THE 15TH INTERNATIONAL CONGRESS ON CARDIOVASCULAR PHARMACOTHERAPY

Program

SUNDAY, OCTOBER 11, 2009

Drugs to Reduce Cardiovascular Risk

Co-chair: Jay N. Cohn

Co-chair: Zhu Junren

8:00 Role of endothelium in vascular and cardiac injury

Paul Vanhoutte

8:20 Lipid lowering drugs for primary and secondary prevention

Rodolfo Paoletti

8:40 Anti-hypertensive therapy: Who is at risk and what is optimal therapy?

William Louis

9:00 Should high-risk patients receive anti-thrombotic therapy and which one?

Nicolas Danchin

9:20 Modern advances in anti-smoking therapy

John McNeil

9:40 Neufeld Lecture

Atheromatous plaque regression

Juan Carlos Kaski

10:15 Break

Joint ISCP-GWIIC Program

Co-chair: Willliam Louis

Co-chair: Huo Yong

10:45 CONSIDER – Survey on Cardiovascular Risk Factors in Hypertensive Patients in China

Zhao Dong

11:05 Management of hypertension: From hypertensive guidelines to clinical practice

Wang Jiguang

11:25 Statins: The cornerstone of anti-atherosclerosis treatment

Zhao Shuiping

11:45 Cholesterol management recommendations for hypertensive patients

Zhang Weizhong

12:05 Lunch

Neurohormonal Inhibition in Cardiovascular Therapy

Co-chair: Dennis Cokkinos

Co-chair: Yan Xiaowei

1:30 The renin-angiotensin system

Jay N. Cohn

1:50 Aldosterone inhibition and cardiovascular protection: More important than it once appeared

Felipe Martinez

2:10 Which beta blocker is most effective in heart failure?

Willem Remme

Drug Treatment of Arrhythmias

2:30 Management of atrial fibrillation

Gheorghe-Andrei Dan

2:50 Management of ventricular arrhythmias

Ali Oto

3:10 Break

Management of Acute conditions: Pharmacologic Strategies and New Drugs

Co-chair: Gheorghe-Andrei Dan

Co-chair: Zhu Jun

3:30 Acute coronary syndromes

Nicolas Danchin

3:50 Acute heart failure

Willem Remme

4:10 Medical therapy of acute ST-elevation MI

Dennis Cokkinos

4:30 Adjourn

MONDAY, OCTOBER 12, 2009

Restoring Health to the Heart and Vasculature

Co-chair: Daniel Duprez

Co-chair: Gao Runlin

9:00 Is vascular stiffness a target for therapy?

Daniel Duprez

9:20 Prevention and regression of myocardial remodeling

Dennis Cokkinos

9:40 Drugs to relieve myocardial ischemia

Alex Battler

10:00 Relative benefit of blood pressure reduction in reducing cardiovascular risk

William Louis

10:20 Discussion

10:30 Break

Controversies in Cardiovascular Therapy I

Co-chair: Miran Kenda

Co-chair: Chen Yundai

11:00 Is pharmacotherapy appropriate in the elderly?

Miran Kenda

11:20 What is the best regimen for inhibiting the renin-angiotensin system?

Felipe Martinez

11:40 Drug therapy vs. mechanical reperfusion in chronic stable angina

Alex Battler

12:00 Lunch

Controversies in Cardiovascular Therapy II

Co-chair: Juan Carlos Kaski

Co-chair: Hu Dayi

1:30 How to best identify candidates for pharmacoprevention

Jay N. Cohn

1:50 Should aspirin be used for primary prevention?

John McNeil

2:10 Is HDL still a target for therapy?

Rodolfo Paoletti

2:30 Secondary prevention of CAD with ACE inhibitors: Struggle between life and death of the endothelium

Roberto Ferrari

2:50 Do oral anti-diabetic drugs reduce cardiovascular disease risk?

Daniel Duprez

3:10 Do new antianginal drugs represent a therapeutic advance?

Juan Carlos Kaski

3:30 Critical issues in the ACC/AHA secondary prevention guidelines

Sidney Smith

3:50 Adjourn